Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects

Phase 1 Recruiting 104 enrolled Beijing InnoCare Pharma Tech Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects

Timeline

Start: 2026-03-13
Primary completion: 2026-09
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ICP-538	Unknown	—	—

Indications

No indication recorded.